Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liping Pang

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Clinical Rheumatology|October 4, 2018
The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trialXia Liu, Xiaomei Li, Xiangpei Li, et al.
Oncology and Therapy|December 16, 2023
Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase InhibitorsHong Chen, Yan Wen, Yun Zeng, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 9, 2024
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective StudyXiaoshuai Zhang, Na Xu, Yunfan Yang, et al.
Blood|July 24, 2024
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapyXiaoshuai Zhang, Bingcheng Liu, Jian Huang, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Clinical Rheumatology|October 4, 2018
The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trialXia Liu, Xiaomei Li, Xiangpei Li, et al.
Oncology and Therapy|December 16, 2023
Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase InhibitorsHong Chen, Yan Wen, Yun Zeng, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 9, 2024
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective StudyXiaoshuai Zhang, Na Xu, Yunfan Yang, et al.
Blood|July 24, 2024
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapyXiaoshuai Zhang, Bingcheng Liu, Jian Huang, et al.
Pageof 7